Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.

Cell reports. Medicine·2026

Same author

Effectiveness of a telemonitoring injury prevention protocol on athletic performance in elite footballers: A randomized prospective controlled study.

Journal of back and musculoskeletal rehabilitation·2025

Same author

The role of extracorporeal CO<sub>2</sub> removal from pathophysiology to clinical applications with focus on potential combination with RRT: an expert opinion document.

Frontiers in medicine·2025

Same author

Characteristics of SARS-CoV-2-associated severe episodes of monoclonal gammopathy-associated capillary leak syndrome (Clarkson disease).

Annals of intensive care·2025

Same author

A Robust siRNA Screening Approach with Optimized Conditions for Large-Scale Transfection in Multiple Human Cancer Cell Lines.

Methods in molecular biology (Clifton, N.J.)·2025

Same author

Clarkson disease in critically and non-critically ill patients: insights from the Italian IRIS-CLS registry.

Internal and emergency medicine·2025

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

Target validation to biomarker development: focus on RNA interference.

Riccardo Colombo¹, Jürgen Moll

¹Nerviano Medical Sciences Srl, Nerviano, Italy.

Molecular Diagnosis & Therapy

|April 22, 2008

Summary

This summary is machine-generated.

RNA interference (RNAi) is crucial for validating cancer drug targets. This method enables rapid loss-of-function studies, identifying and validating oncology targets and biomarkers effectively.

More Related Videos

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay

Published on: May 25, 2015

Related Experiment Videos

Last Updated: Jul 5, 2026

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay

Published on: May 25, 2015

Area of Science:

Molecular Biology
Drug Discovery
Oncology

Background:

Increasingly, the pharmaceutical industry faces economic pressure to validate molecular targets, especially in cancer drug development.
Biomarkers are vital for proving mechanism of action in preclinical drug development, reducing clinical attrition rates.

Purpose of the Study:

To review the role of RNA interference (RNAi) as a key technology for target validation and identification.
To highlight the application of RNAi in academic and industrial settings for preclinical drug development.

Main Methods:

RNA interference (RNAi) leverages a natural cellular mechanism for post-transcriptional gene regulation.
Small-interfering RNA (siRNA) and short-hairpin RNA (shRNA) design and delivery are critical components.
Minimizing off-target effects is essential for accurate validation studies.

Main Results:

RNAi facilitates rapid loss-of-function experiments to observe phenotypes upon target gene abrogation.
The technique has demonstrated success in identifying and validating numerous oncology targets.
RNAi has proven effective in discovering and validating cancer biomarkers.

Conclusions:

RNA interference (RNAi) is the method of choice for target validation and identification in drug discovery.
This technology significantly aids in reducing drug candidate attrition by validating targets early in development.
Successful applications in oncology demonstrate the power of RNAi for identifying novel therapeutic targets and biomarkers.